Payment overview · 2025
General Payments
$2,564.58
116 reported records · 22 companies
Healthcare provider profile · identity verified
William H Ward, RN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · OPELIKA, AL · NPI 1376106922
Verified facts
What the public records show
CMS Open Payments records show William H Ward, RN received $2,564.58 in general payments during 2025 across 116 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $474.48 | 18.5% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $231.64 | 9.0% | 13 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$218.16 | 8.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $213.42 | 8.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.54 | 7.7% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $160.13 | 6.2% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $154.85 | 6.0% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.98 | 6.0% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $115.04 | 4.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.39 | 4.3% | 6 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $104.05 | 4.1% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $85.39 | 3.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.59 | 3.2% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.55 | 1.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.04 | 1.5% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $35.41 | 1.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.25 | 1.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.68 | 1.3% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $31.19 | 1.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.82 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.73 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.25 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,564.58 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $229.06 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.34 | 7 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $218.16 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $202.87 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $193.15 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.07 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $160.13 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $154.85 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $143.12 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.58 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $115.04 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $110.39 | 6 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $104.05 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $95.76 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.29 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $85.39 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.55 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.49 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.38 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.25 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.68 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $25.20 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.25 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $10.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $5.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
72 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Hyclate | Doxycycline Hyclate | 336 | 271 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 273 | 227 |
| Azithromycin | Azithromycin | 255 | 200 |
| Methylprednisolone | Methylprednisolone | 117 | 96 |
| Fluconazole | Fluconazole | 100 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 96 | 59 |
| Cephalexin | Cephalexin | 87 | 71 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 68 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 45 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 68 |
| Mupirocin | Mupirocin | 73 | 68 |
| Paxlovid | Nirmatrelvir/Ritonavir | 72 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 38 |
| Ondansetron Odt | Ondansetron | 63 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 29 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 54 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 41 |
| Omeprazole | Omeprazole | 51 | 26 |
| Potassium Chloride | Potassium Chloride | 50 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 20 |
| Losartan Potassium | Losartan Potassium | 42 | 20 |
| Levofloxacin | Levofloxacin | 40 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 20 |
| Trazodone Hcl | Trazodone Hcl | 35 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 34 | 23 |
| Famotidine | Famotidine | 34 | 14 |
| Lisinopril | Lisinopril | 34 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 34 | 18 |
| Meloxicam | Meloxicam | 33 | 23 |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Furosemide | Furosemide | 26 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 24 |
| Sucralfate | Sucralfate | 24 | 17 |
| Metformin Hcl | Metformin Hcl | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Nystatin | Nystatin | 19 | 12 |
| Lagevrio (Eua) | Molnupiravir | 18 | 18 |
| Metronidazole | Metronidazole | 18 | 17 |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 15 |
| Ofloxacin | Ofloxacin | 15 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 12 |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,564.58 · 116 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FANAPT, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, INSPIRE, JARDIANCE, Kerendia, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error